The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28131714 |
119 |
Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-a/ß. |
Novartis Institutes for BioMedical Research |
| 1597853 |
2 |
A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. |
National Cancer Institute-Frederick |
| 1992155 |
30 |
Design of potent protein kinase inhibitors using the bisubstrate approach. |
URA CNRS 1309 |
| 2342075 |
11 |
Synthesis of quaternary amine ether lipids and evaluation of neoplastic cell growth inhibitory properties. |
University of North Carolina |
| 11454465 |
4 |
Synthesis of N-alkyl substituted indolocarbazoles as potent inhibitors of human cytomegalovirus replication. |
GlaxoSmithKline |
| 27117263 |
51 |
Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKC¿ inhibitors. |
Takeda Pharmaceutical Co., Ltd |
| 26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School of Medicine at Mount Sinai |
| 25000588 |
72 |
Discovery of selective and orally bioavailable protein kinase C¿ (PKC¿) inhibitors from a fragment hit. |
AbbVie Bioresearch Center |
| 24684293 |
17 |
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C¿ and¿ from typical C1 domains. |
National Cancer Institute-Bethesda |
| 23394126 |
170 |
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). |
Exelixis Inc |
| 23398373 |
88 |
Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases. |
Vertex Pharmaceuticals Inc |
| 21251828 |
44 |
Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. |
MSD |
| 23103095 |
125 |
Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors. |
Abbott Laboratories |
| 22726925 |
216 |
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. |
Cellzome Ltd |
| 21797275 |
139 |
Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. |
Novartis Institutes for BioMedical Research |
| 22078216 |
146 |
2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes. |
Novartis Institutes for BioMedical Research |
| 22625994 |
28 |
Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity. |
Kyoto University |
| 22738630 |
76 |
Structure-based optimization of aminopyridines as PKC¿ inhibitors. |
Vertex Pharmaceuticals Inc |
| 20000469 |
179 |
Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. |
Boehringer Ingelheim Pharmaceuticals Inc |
| 20100661 |
21 |
Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C. |
University of Houston |
| 19703774 |
56 |
C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II. |
Wyeth Research |
| 18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
| 9677190 |
49 |
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. |
University of California |
| 18434148 |
43 |
Synthesis and PKCtheta inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles. |
Wyeth Research |
| 18359226 |
50 |
Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. |
Bristol-Myers Squibb Research and Development |
| 18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University of Oxford |
| 17977729 |
40 |
Design and physicochemical properties of new fluorescent ligands of protein kinase C isozymes focused on CH/pi interaction. |
Kyoto University |
| 17935989 |
146 |
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics. |
Abbott Laboratories |
| 16876403 |
85 |
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. |
Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories |
| 16460940 |
13 |
Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. |
Hoffmann-La Roche Inc |
| 15369389 |
4 |
Conformationally constrained analogues of diacylglycerol (DAG). 23. Hydrophobic ligand-protein interactions versus ligand-lipid interactions of DAG-lactones with protein kinase C (PK-C). |
National Cancer Institute-Frederick |
| 12672248 |
50 |
Kinase inhibitors: not just for kinases anymore. |
Northwestern University |
| 12166950 |
208 |
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. |
Millennium Pharmaceuticals Inc |
| 8289196 |
7 |
New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. |
University of North Carolina |
| 10999477 |
40 |
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V. |
Kyoto University |
| 10843211 |
38 |
Structure-activity relationship studies of flavopiridol analogues. |
Mitotix Inc |
| | 80 |
Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure |
TBA |
| 15953730 |
13 |
RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. |
Hoffmann-La Roche Inc |
| 22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). |
Ansaris |
| 21975067 |
12 |
Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. |
University of Houston |
| 22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
| 21705217 |
60 |
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38a MAP kinase inhibitors. |
Bristol-Myers Squibb Co. |
| 21696964 |
12 |
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP. |
Keio University |
| 21035336 |
42 |
5-amino-pyrazoles as potent and selective p38a inhibitors. |
Bristol-Myers Squibb Research and Development |
| 20817520 |
40 |
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity. |
Kyoto University |
| 19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). |
Ambit Biosciences |
| 16372404 |
1 |
Actin is the primary cellular receptor of bistramide A. |
University of Chicago |
| 20684591 |
87 |
Identification of orally available naphthyridine protein kinase D inhibitors. |
Novartis Institutes for BioMedical Research |
| 20346655 |
117 |
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. |
Abbott Laboratories |
| 20153643 |
68 |
Optimization of 5-vinylaryl-3-pyridinecarbonitriles as PKCtheta inhibitors. |
Wyeth Research |
| 19854645 |
87 |
Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles. |
Wyeth Research |
| 19926477 |
100 |
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization. |
Abbott Laboratories |
| 19762237 |
58 |
First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. |
Wyeth Research |
| 19682896 |
49 |
C-5 Substituted heteroaryl 3-pyridinecarbonitriles as PKCtheta inhibitors: Part I. |
Wyeth Research |
| 8176401 |
21 |
Anti-AIDS Agents, 11. Betulinic Acid and Platanic Acid as Anti-HIV Principles from Syzigium claviflorum, and the Anti-HIV Activity of Structurally Related Triterpenoids |
TBA |
| | 4 |
Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CK II |
TBA |
| | 5 |
Novel conformationally constrained analogues of diacylglycerol. Protein kinase C binding affinity of simplified compounds based on a 6-membered lactam moiety |
TBA |
| | 42 |
A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation |
TBA |
| | 230 |
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives |
TBA |
| | 99 |
Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors |
TBA |
| | 77 |
Synthesis and protein kinase C inhibitory activities of indane analogs of balanol |
TBA |
| | 70 |
Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moiety |
TBA |
| | 90 |
Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors |
TBA |
| | 107 |
Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors of protein kinase C |
TBA |
| | 40 |
Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol |
TBA |
| | 40 |
Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol |
TBA |
| | 75 |
Increasing the cellular PKC inhibitory activity of balanol: A study of ester analogs |
TBA |
| | 88 |
Novel PKC inhibitory analogs of balanol with replacement of the ester functionality |
TBA |
| | 40 |
Protein kinase C inhibitory activities of balanol analogs bearing carboxylic acid replacements |
TBA |
| | 7 |
Conformationally constrained analogues of diacylglycerol (DAG). 4. Interaction of α-alkylidene-γ-lactones with protein kinase C (PK-C) |
TBA |
| 19447612 |
59 |
Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCtheta inhibitors. |
Wyeth Research |
| 19438240 |
8 |
Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. |
University of Helsinki |
| 19379015 |
40 |
Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths. |
National Cancer Institute-Frederick |
| 19111463 |
46 |
Second generation 4-(4-methyl-1H-indol-5-ylamino)-2-phenylthieno[2,3-b]pyridine-5-carbonitrile PKCtheta inhibitors. |
Wyeth Research |
| 18606543 |
68 |
2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta. |
Wyeth Research |
| 17875639 |
12 |
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits. |
University of California San Francisco |
| 18072722 |
42 |
Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes. |
Kyoto University |
| 17658776 |
109 |
Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. |
Abbott Laboratories |
| 17303421 |
56 |
Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. |
Roche Research Center |
| 17287122 |
79 |
Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors. |
Abbott Laboratories |
| 16789733 |
41 |
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 16722637 |
39 |
Conformationally constrained analogues of diacylglycerol. 26. Exploring the chemical space surrounding the C1 domain of protein kinase C with DAG-lactones containing aryl groups at the sn-1 and sn-2 positions. |
National Cancer Institute-Frederick |
| 16682193 |
62 |
Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 16640328 |
13 |
Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. |
Kyoto University |
| 16216497 |
67 |
Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. |
Abbott Bioresearch Center |
| 16134942 |
19 |
Conformationally constrained analogues of diacylglycerol (DAG). 25. Exploration of the sn-1 and sn-2 carbonyl functionality reveals the essential role of the sn-1 carbonyl at the lipid interface in the binding of DAG-lactones to protein kinase C. |
National Cancer Institute-Frederick |
| 15771419 |
134 |
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety. |
Johnson & Johnson Pharmaceutical Research & Development |
| 15615512 |
21 |
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 15566298 |
34 |
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. |
Bristol-Myers Squibb Co. |
| 15317463 |
16 |
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 14552791 |
35 |
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. |
Eli Lilly and Company |
| 12954072 |
46 |
New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity. |
Georgetown University Medical Center |
| 12941331 |
96 |
Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. |
Johnson & Johnson Pharmaceutical Research & Development |
| 12941324 |
66 |
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes. |
Kyoto University |
| 12824047 |
99 |
Novel IKK inhibitors: beta-carbolines. |
Millennium Pharmaceuticals Inc |
| 12749884 |
126 |
Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. |
Eli Lilly and Company |
| 12672234 |
64 |
Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase. |
Boehringer Ingelheim Pharmaceuticals Inc |
| 12270156 |
8 |
Synthesis and kinase inhibitory activity of 3'-(S)-epi-K-252a. |
Cephalon Inc |
| 12039590 |
51 |
Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. |
Abbott Bioresearch Center |
| 11909733 |
30 |
Beta-carbolines as specific inhibitors of cyclin-dependent kinases. |
Institute of Molecular and Cell Biology |
| 11327599 |
25 |
Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth. |
Georgetotwn University |
| 11297449 |
3 |
Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta. |
University of Tennessee College of Medicine |
| 11266178 |
39 |
The amide hydrogen of (-)-indolactam-V and benzolactam-V8's plays a critical role in protein kinase C binding and tumor-promoting activities. |
Kyoto University |
| 11266177 |
26 |
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding. |
Kyoto University |
| 11206480 |
6 |
Synthesis of 7,8-disubstituted benzolactam-V8 and its binding to protein kinase C. |
Institute of Organic Chemistry |
| 11012021 |
69 |
Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. |
BASF Bioresearch Corporation |
| 10743939 |
63 |
Synthesis and biological activities of NB-506 analogues modified at the glucose group. |
Banyu Tsukuba Research Institute |
| 10636245 |
4 |
Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. |
University of Tokyo |
| 10612598 |
29 |
4-Pyridin-5-yl-2-(3,4,5-trimethoxyphenylamino)pyrimidines: potent and selective inhibitors of ZAP 70. |
Celltech Therapeutics Limited |
| 10612590 |
56 |
Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings. |
Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories |
| 10498208 |
4 |
Protein kinase C modulators bearing dicarba-CLOSO-dodecaborane as a hydrophobic pharmacophore. |
University of Tokyo |
| 10397502 |
36 |
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes. |
Stanford University |
| 9554881 |
11 |
Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase Cdelta by synthesis of hydrophobically modified, teleocidin-mimicking benzolactams and computational docking simulation. |
University of Tokyo |
| 9135029 |
29 |
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity. |
Georgetown University Medical Center |
| 9003521 |
249 |
Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety. |
Eli Lilly and Company |
| 8709095 |
87 |
(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. |
Eli Lilly and Company |
| 26509640 |
234 |
Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders. |
AbbVie Bioresearch Center |
| 24332494 |
16 |
Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer. |
LEO Pharma A/S |
| 23993332 |
8 |
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer. |
LEO Pharma A/S |
| 23803585 |
7 |
Effects of the methoxy group in the side chain of debromoaplysiatoxin on its tumor-promoting and anti-proliferative activities. |
Kyoto University |
| 23582444 |
20 |
Structure-activity studies on the side chain of a simplified analog of aplysiatoxin (aplog-1) with anti-proliferative activity. |
Kyoto University |
| 21388717 |
1 |
Glycoglycerolipid analogues inhibit PKC translocation to the plasma membrane and downstream signaling pathways in PMA-treated fibroblasts and human glioblastoma cells, U87MG. |
University of Milan |
| 7807122 |
4 |
New cytotoxic peroxylactones from the marine sponge, Plakinastrella onkodes. |
Harbor Branch Oceanographic Institution, Inc. |
| 17618015 |
13 |
Bioactive peroxides as potential therapeutic agents. |
The Hebrew University of Jerusalem |
| 10052965 |
9 |
Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. |
Universit£ Blaise Pascal |
| 9572888 |
4 |
Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. |
Universit£ Blaise Pascal |
| 14505650 |
12 |
An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. |
Northwestern University |
| 27731641 |
5 |
Isolation of Phorbol Esters from Euphorbia grandicornis and Evaluation of Protein Kinase C- and Human Platelet-Activating Effects of Euphorbiaceae Diterpenes. |
Kaohsiung Medical University |
| 30274941 |
36 |
A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model. |
Astellas Pharma Inc. |
| 29135244 |
5 |
Natural Products with Heteroatom-Rich Ring Systems. |
University of Auckland |
| 29578342 |
35 |
Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors. |
Yunnan University |
| 29870245 |
39 |
Discovery of Novel Small-Molecule Inhibitors of NF-?B Signaling with Antiinflammatory and Anticancer Properties. |
University of Colorado |
| 29860841 |
140 |
?-Arylidene Diacylglycerol-Lactones (DAG-Lactones) as Selective Ras Guanine-Releasing Protein 3 (RasGRP3) Ligands. |
Seoul National University |
| 28991459 |
71 |
Methyl 3-(3-(4-(2,4,4-Trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a Novel and Dual Malate Dehydrogenase (MDH) 1/2 Inhibitor Targeting Cancer Metabolism. |
Dongguk University |
| 27943581 |
8 |
Reverse Biosynthesis: Generating Combinatorial Pools of Drug Leads from Enzyme-Mediated Fragmentation of Natural Products. |
The University of Sydney |
| 27128528 |
42 |
Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. |
Harvard Medical School |
| 2176210 |
48 |
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. |
Ciba-Geigy Ltd |
| 11454905 |
22 |
[3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. |
Eli Lilly and Company |
| 11121615 |
32 |
Synthesis and in vitro opioid activity profiles of DALDA analogues. |
Clinical Research Institute of Montreal |
| 16236500 |
26 |
Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. |
Johnson & Johnson Pharmaceutical |
| 15689148 |
19 |
Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. |
Shanghai Institute of Materia Medica |
| 15664516 |
21 |
Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases. |
University of Dundee |
| 15026054 |
55 |
Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. |
CNRS |
Search and Browse
